← All trials
NCT07096128
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 20, 2024
- Primary completion
- May 31, 2026
- Completion date
- Apr 30, 2027
- First posted
- Jul 31, 2025
- Last posted
- Jul 31, 2025
- Enrollment
- 36
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- People's Liberation Army of ChinaLead sponsor
- Sinotau Pharmaceutical GroupCollaborator
- People's Liberation Army of ChinaOfficial
- People's Liberation Army of ChinaSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.